Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

International Journal of Cancer

Volumn 129, Issue 11, 2011, Pages 2632-2642

  Haupt, Richard M ^a   Wheeler, Cosette M ^b   Brown, Darron R ^c   Garland, Suzanne M ^d,e   Ferris, Daron G ^f   Paavonen, Jorma A ^g   Lehtinen, Matti O ^h   Steben, Marc ⁱ   Joura, Elmar A ^j   Giacoletti, Katherine E D ^a   Radley, David R ^a   James, Margaret K ^a   Saah, Alfred J ^a   Sings, Heather L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁱ INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

cervical intraepithelial neoplasia; HPV vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 79960130975     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25940     Document Type: Article

References (31)

1. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin KL, Gacic M, Beauvais O, Albero G, Ferrer E, et al. HPV and cervical cancer in the word. 2007 report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV information centre). Available at. [accessed 5/10/2010].
2. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer A, Shah KV, Snijders PJF,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9. (Pubitemid 29406813)
3. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsaguë X, Shah KV, Snijders PJF, Meijer CJLM,; for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. (Pubitemid 36159887)
4. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura E,. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199: 805-14.
5. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD,. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191: 182-92. (Pubitemid 40096375)
6. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ,. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008; 98: 646-51. (Pubitemid 351214513)
7. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65. (Pubitemid 39488060)
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G,. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367: 1247-55.
9. Harper DM,. Impact of vaccination with CervarixTM on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 2008; 110: S11-7.
10. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, De Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70. (Pubitemid 46977438)
11. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
12. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan JT, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43. (Pubitemid 46740303)
13. The FUTURE II Study Group,. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
14. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
15. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GWK, Ferris DG, Steben M, Jones RW, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007; 369: 1693-702. (Pubitemid 46783792)
16. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M,. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9. (Pubitemid 41417924)
17. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA,. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 1272-8.
18. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-6. (Pubitemid 37518501)
19. Villa LL, Ault K, Giuliano AR, Costa RLR, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24: 5571-83. (Pubitemid 44172918)
20. Olsson S-E, Villa LL, Costa R, Petta C, Andrade R, Malm C, Iversen O-E, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 2007; 25: 4931-9. (Pubitemid 46843434)
21. Olsson S-E, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5: 696-704.
22. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson S-E, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8. (Pubitemid 40590263)
23. Henry MR,. The Bethesda system 2001: an update of new terminology for gynecologic cytology. Clin Lab Med 2003; 23: 585-603. (Pubitemid 37175546)
24. WO 2003/019143 A2 (awarded to K. Jansen), WO 2006/116276 A2 (awarded to F. Taddeo) and WO 2006/116303 A2. Available at 2008.
25. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E,. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
26. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12: 959-69.
27. Stanley M,. Immune responses to human papillomavirus. Vaccine 2006; 24: S16-22.
28. Kapeu AS, Luostarinen T, Jellum E, Dillner J, Hakama M, Koskela P, Lenner P, Love A, Mahlamaki E, Thoresen S, Tryggvadottir L, Wadell G, et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 2009; 169: 480-8.
29. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR,. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-53. (Pubitemid 47263157)
30. Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky L, Tay EH, Garcia P, Ault K, et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naive women aged 16-26. J Infect Dis 2009; 199: 926-35.
31. The FUTURE II Study Group,. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. J Infect Dis 2007; 196: 1438-46.